Medical Doctor Program year 2023 Reported 2020–2023 Source: CMS Open Payments, 2026 publication

Dimitrios Giannakidis

Vascular Neurology San Francisco, CA Medical Doctor

NPI 1285963793 CMS profile 855943

1100 Van Ness Ave, San Francisco, CA 94109

Open in the dashboard

General payments

$359

13 records reported · program years 2020–2023

Research payments

$0

Paid to them · None reported · program years 2020–2023

Ownership & investment interest

$0

None reported

Through program year 2023, Dimitrios Giannakidis of San Francisco, CA is reported in the CMS Open Payments database as having received $359 across 13 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 36th percentile of Vascular Neurology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

4 rows
Year Kind Relative to this record's peak year Amount Records
2023 General $13 1
2022 General $24 1
2021 General $73 4
2020 General $249 7

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Dimitrios Giannakidis
  • Vascular Neurology median
  • Middle half of Vascular Neurology
  • National median

In program year 2025, general payments to Dimitrios Giannakidis were reported at $0. Among 416 Vascular Neurology profiles paid that year, the median was $360 and the middle half received between $91 and $1,472.

Show as a table
Year Dimitrios Giannakidis Vascular Neurology median Middle half National median
2019 $0 $263 $102–$1,640 $163
2020 $249 $153 $45–$1,000 $114
2021 $73 $261 $100–$1,355 $132
2022 $24 $242 $87–$1,273 $149
2023 $13 $322 $97–$1,266 $160
2024 $0 $247 $70–$1,053 $164
2025 $0 $360 $91–$1,472 $169

Breakdown

Who paid General payments · program years 2020–2023
  1. Imperative Care, INc $159 2 payments
  2. Avanir Pharmaceuticals, Inc. $57 3 payments
  3. Teva Pharmaceuticals USA, Inc. $37 2 payments
  4. SK Life Science, Inc. $24 1 payment
  5. Amgen Inc. $21 1 payment
  6. Acorda Therapeutics, Inc $18 1 payment
  7. Mitsubishi Tanabe Pharma America, Inc. $16 1 payment
  8. Alkermes, Inc. $14 1 payment
  9. AbbVie, Inc. $13 1 payment

Every payment, record by record

What the payments were for General payments · program years 2020–2023
  1. Food and Beverage $341 12 payments
  2. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $18 1 payment
Products named General payments · program years 2020–2023
  1. Imperative Care Zoom $159 2 payments
  2. Imperative Care TracStar $159 2 payments
  3. NUEDEXTA $57 3 payments
  4. AJOVY $37 2 payments
  5. AVSOLA $21 1 payment
  6. INBRIJA $18 1 payment
  7. RADICAVA $16 1 payment
  8. ARISTADA Cns $14 1 payment
  9. ARISTADA Cns $14 1 payment
  10. ARISTADA Cns $14 1 payment
  11. Other $42 3 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Billing to Medicare

Part B · data year 2024 · 42 billing codes

Paid by Medicare

$132,321

Of which drugs: $2,583

Medicare patients

861

Average age 74

Services billed

5,568

526 women, 335 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 52%
Depression 35%
Diabetes 33%
Chronic kidney disease 33%
Ischemic heart disease 32%
Atrial fibrillation 24%
Heart failure 21%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, gadobenate dimeglumine (multihance multipack), per ml A9578 Office 158 1,423 $1,958
Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml Q9967 Office 33 3,030 $322

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

13 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Vascular Neurology in California

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2023

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record